1. Scrip
  2. >>Business
  3. >>Deals

Takeda Adds To Its Celiac Pipeline With Innate-Discovered Antibodies

 
• By Joseph Haas

Deal Snapshot: Using antibodies against an undisclosed target discovered and engineered by Innate, Takeda plans to investigate the potential of antibody-drug conjugates in celiac disease

GI disease
Takeda keeps investing in celiac disease as part of its GI therapy focus • Source: Shutterstock

Who: Takeda/Innate Pharma

What: Takeda is licensing antibodies discovered by Innate for use in antibody-drug conjugate

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business